Systematic review reveals substantial heterogeneity in methods assessing progression-free survival as an oncology trial surrogate, highlighting the need for standardized evaluation guidelines.
Although most studies used a meta-analytic approach as recommended, our methodological review highlights heterogeneity in methods and reporting, which stresses the importance of developing and applying clear recommendations in this area.
No takes yet. Share an insight, caveat, or question.
Belin et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: